FDA Approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata

Deuruxolitinib, a Janus kinase (JAK) inhibitor, has received FDA approval as a new treatment option for severe alopecia areata (AA), an autoimmune disorder affecting 1-2% of the population. AA is characterized by patchy, non-scarring hair loss due to the infiltration of cytotoxic T cells into hair follicles, driven by cytokines like IFN-γ and IL-15. These cytokines activate JAK signaling pathways, exacerbating the immune response. Deuruxolitinib targets these pathways, offering a promising therapeutic approach for individuals with severe AA.